Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism.

The journal of physical chemistry. B - 16 May 2024

Chakraborti Ananya, Tardiff Jil C, Schwartz Steven D

Abstract excerpt

Hypertrophic cardiomyopathy is one of the most common forms of genetic cardiomyopathy. Mavacamten is a first-in-class myosin modulator that was identified via activity screening on the wild type, and it is FDA-approved for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The drug selectively binds to the cardiac β-myosin, inhibiting myosin function to decrease cardiac contractility. Though the drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Benzylamines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biocatalysis

Share to Cardiomyopathy, Hypertrophic

Share to Hydrolysis

Share to Molecular Dynamics Simulation

Share to Myosins

Share to Uracil

Source

Open in PubMed Open full text

Identifiers

PMID: 38708944
DOI: 10.1021/acs.jpcb.4c01601
PMCID: PMC11103257

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism.PMID 38708944Read ↗

Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.Semantic proximity Read ↗

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapiesSemantic proximity Read ↗

Screening single nucleotide changes to tropomyosin to identify novel cardiomyopathy mutants.Semantic proximity Read ↗

The G256E HCM mutation prolongs relaxation via altered nucleotide handlingSemantic proximity Read ↗

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Altered contractility in mutation-specific hypertrophic cardiomyopathy: a mechano-energetic in silico study with pharmacological insightsSemantic proximity Read ↗

Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin TSemantic proximity Read ↗

The hypertrophic cardiomyopathy myosin mutation R453C alters ATP binding and hydrolysis of human cardiac β-myosin.Semantic proximity Read ↗

Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar propertiesSemantic proximity Read ↗

Integrating comparative modeling and accelerated simulations reveals conformational and energetic basis of actomyosin force generationSemantic proximity Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

Myosin motor domains carrying mutations implicated in early or late onset Hypertrophic Cardiomyopathy have similar propertiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.